Tag Archives: Jamie Dimon

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

JP Morgan Healthcare Conference Marked by Uncertainty

2012 J.P. Morgan Healthcare Conference Marked by Uncertainty Audrey S. Erbes, Principal, Erbes & Associates, outlines the highlights of this week’s event in San Francisco. One of the few positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of […]
Posted in Guest Blog, healthcare, R&D, Strategy | Also tagged , , , | 2 Comments
  • Categories

  • Meta